JP2019529472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529472A5 JP2019529472A5 JP2019516442A JP2019516442A JP2019529472A5 JP 2019529472 A5 JP2019529472 A5 JP 2019529472A5 JP 2019516442 A JP2019516442 A JP 2019516442A JP 2019516442 A JP2019516442 A JP 2019516442A JP 2019529472 A5 JP2019529472 A5 JP 2019529472A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound according
- pharmaceutical composition
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C[C@@](C(C1O)O)O[C@]1N(C=CC(N1Cc(cc2-c3ccccc3)ncc2F)=O)C1=O Chemical compound *C[C@@](C(C1O)O)O[C@]1N(C=CC(N1Cc(cc2-c3ccccc3)ncc2F)=O)C1=O 0.000 description 1
- TYIWPBWUTGRKGT-VWRAKTAISA-N Cc1c(CN(C(C=CN2CC(CO[C@@H]3CO)(C3O)O)=O)C2=O)nccc1-c1ccccc1 Chemical compound Cc1c(CN(C(C=CN2CC(CO[C@@H]3CO)(C3O)O)=O)C2=O)nccc1-c1ccccc1 TYIWPBWUTGRKGT-VWRAKTAISA-N 0.000 description 1
- AVKIFKMDHWOPPA-WYNBGMTASA-N Cc1cc(-c2ccccc2)cc(CN(C(C=CN2[C@@H](C3O)O[C@H](CO)C3O)=O)C2=O)n1 Chemical compound Cc1cc(-c2ccccc2)cc(CN(C(C=CN2[C@@H](C3O)O[C@H](CO)C3O)=O)C2=O)n1 AVKIFKMDHWOPPA-WYNBGMTASA-N 0.000 description 1
- LADNXXNDLAEQAA-WYNBGMTASA-N Cc1cnc(CN(C(C=CN2[C@@H](C3O)O[C@H](CO)C3O)=O)C2=O)cc1-c1ccccc1 Chemical compound Cc1cnc(CN(C(C=CN2[C@@H](C3O)O[C@H](CO)C3O)=O)C2=O)cc1-c1ccccc1 LADNXXNDLAEQAA-WYNBGMTASA-N 0.000 description 1
- OVVSVZWQPYOFSG-SGZDXZSOSA-N OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc(nc2)cc(-c3ccccc3)c2Cl)=O)C1=O Chemical compound OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc(nc2)cc(-c3ccccc3)c2Cl)=O)C1=O OVVSVZWQPYOFSG-SGZDXZSOSA-N 0.000 description 1
- RNZYZIJVYCNWMP-BTWUCOSQSA-N OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc(nccc2-c3ccccc3)c2Cl)=O)C1=O Chemical compound OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc(nccc2-c3ccccc3)c2Cl)=O)C1=O RNZYZIJVYCNWMP-BTWUCOSQSA-N 0.000 description 1
- BIVFCCSHYQXVJV-BTWUCOSQSA-N OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc2nc(C(F)(F)F)cc(-c3ccccc3)c2)=O)C1=O Chemical compound OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc2nc(C(F)(F)F)cc(-c3ccccc3)c2)=O)C1=O BIVFCCSHYQXVJV-BTWUCOSQSA-N 0.000 description 1
- GNBVVAPNOLAERL-BTWUCOSQSA-N OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc2nccc(-c3ccccc3)c2C(F)(F)F)=O)C1=O Chemical compound OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc2nccc(-c3ccccc3)c2C(F)(F)F)=O)C1=O GNBVVAPNOLAERL-BTWUCOSQSA-N 0.000 description 1
- ZQEKWMVTBSRIBS-FEPNQTLGSA-N OC[C@H](C1O)OCC1(CN(C=CC(N1Cc(nccc2-c3ccccc3)c2F)=O)C1=O)O Chemical compound OC[C@H](C1O)OCC1(CN(C=CC(N1Cc(nccc2-c3ccccc3)c2F)=O)C1=O)O ZQEKWMVTBSRIBS-FEPNQTLGSA-N 0.000 description 1
- QSVXHHJYMKZCAL-HOHBBMLPSA-N OC[C@H](C1O)OCC1(CN(C=CC(N1Cc2ncc(C(F)(F)F)c(-c3ccccc3)c2)=O)C1=O)O Chemical compound OC[C@H](C1O)OCC1(CN(C=CC(N1Cc2ncc(C(F)(F)F)c(-c3ccccc3)c2)=O)C1=O)O QSVXHHJYMKZCAL-HOHBBMLPSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662399691P | 2016-09-26 | 2016-09-26 | |
| US62/399,691 | 2016-09-26 | ||
| PCT/US2017/053565 WO2018058148A1 (en) | 2016-09-26 | 2017-09-26 | Uridine nucleoside derivatives, compositions and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529472A JP2019529472A (ja) | 2019-10-17 |
| JP2019529472A5 true JP2019529472A5 (enExample) | 2020-11-12 |
| JP7121731B2 JP7121731B2 (ja) | 2022-08-18 |
Family
ID=61690038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516442A Expired - Fee Related JP7121731B2 (ja) | 2016-09-26 | 2017-09-26 | ウリジンヌクレオシド誘導体、組成物及び使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200040025A1 (enExample) |
| EP (1) | EP3515447A4 (enExample) |
| JP (1) | JP7121731B2 (enExample) |
| CA (1) | CA3038519A1 (enExample) |
| WO (1) | WO2018058148A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7506473B2 (ja) * | 2019-12-20 | 2024-06-26 | ポッカサッポロフード＆ビバレッジ株式会社 | アミロイドβ蓄積抑制剤 |
| US20230165885A1 (en) * | 2020-03-24 | 2023-06-01 | Gliaguard, Inc. | Treatment of eye disorders with uridine phosphate derivatives |
| TW202321211A (zh) | 2021-08-10 | 2023-06-01 | 美商艾伯維有限公司 | 菸鹼醯胺ripk1抑制劑 |
| CN118401539A (zh) | 2021-12-15 | 2024-07-26 | 兆维生物科技公司 | 官能化的n-乙酰半乳糖胺类似物 |
| US12116382B2 (en) | 2022-11-28 | 2024-10-15 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine analogs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| JPH0344379A (ja) | 1989-07-13 | 1991-02-26 | Yamasa Shoyu Co Ltd | Ｎ↑３―ピペラジノウラシル誘導体 |
| US5859014A (en) * | 1995-06-09 | 1999-01-12 | Syntex (U.S.A.) Inc. | Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists |
| JP2011518841A (ja) | 2008-04-24 | 2011-06-30 | ニューリンク ジェネティクス， インコーポレイテッド | Ｉｄｏ阻害剤 |
| KR20110079197A (ko) * | 2009-12-31 | 2011-07-07 | 제일모직주식회사 | 유기광전소자용 화합물 및 이를 포함하는 유기광전소자 |
| JP6162125B2 (ja) * | 2011-09-30 | 2017-07-12 | タフツ・ユニバーシティ | 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法 |
| US9163055B2 (en) | 2012-09-28 | 2015-10-20 | Tufts University | Methods for treating glaucoma using uridine diphosphate derivatives |
| CN103232509B (zh) | 2013-05-14 | 2015-07-08 | 郑州大学 | 氟尿嘧啶类化合物、其制备方法及其应用 |
-
2017
- 2017-09-26 EP EP17854152.0A patent/EP3515447A4/en not_active Withdrawn
- 2017-09-26 WO PCT/US2017/053565 patent/WO2018058148A1/en not_active Ceased
- 2017-09-26 US US16/336,898 patent/US20200040025A1/en not_active Abandoned
- 2017-09-26 CA CA3038519A patent/CA3038519A1/en not_active Abandoned
- 2017-09-26 JP JP2019516442A patent/JP7121731B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2960598T3 (es) | Compuestos para el tratamiento de enfermedades y trastornos oftálmicos | |
| JP2016513668A5 (enExample) | ||
| RU2526201C2 (ru) | Способ лечения артрита | |
| RU2010116708A (ru) | Бициклическое производное гамма-аминокислоты | |
| CN102421427B (zh) | 用于治疗特定癌症的包含rdea119/bay869766的药物组合 | |
| WO2017035408A1 (en) | Compounds for treatment of immune and inflammatory disorders | |
| WO2017035418A1 (en) | Disubstituted compounds for treatment of immune and inflammatory disorders | |
| WO2017035351A1 (en) | Amino compounds for treatment of medical disorders | |
| KR20050085537A (ko) | 다양한 제약 용도를 위한 알파2델타 리간드 | |
| JP2021530513A5 (enExample) | ||
| JP2005538099A5 (enExample) | ||
| AU2019226587A1 (en) | Afibrotic compounds, devices, and uses thereof | |
| WO2015051327A1 (en) | Treating inflammation using llp2a-bisphosphonate conjugates and mesenchymal stem cells | |
| JP2015532289A5 (enExample) | ||
| US20100087436A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| JP2011207905A (ja) | 脳虚血疾患を予防及び治療する薬剤の製造におけるｌ−ブチルフタリドの使用 | |
| US20240122957A1 (en) | Use of nicotinamide mononucleotide (nmn) for the prevention and/or treatment of rheumatoid arthritis, and corresponding compositions | |
| MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same | |
| JP2019085404A (ja) | 脳腫瘍の治療のための医薬 | |
| JP2023553989A5 (enExample) | ||
| CN1151793C (zh) | 多发性骨髓瘤的骨病变治疗用医药组合物 | |
| WO2022184114A1 (zh) | 抗il-17抗体治疗自身免疫性疾病和炎症的方法 | |
| JP2023500352A (ja) | 移植片対宿主病を予防又は治療するための化合物 | |
| JP2023505690A5 (enExample) | ||
| US20240269120A1 (en) | Method for Treating an Autoimmune and Inflammatory Disease |